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Mucosal-associated invariant T (MAIT) cells are a unique innate-like T cell subset that
responds to a wide array of bacteria and yeast through recognition of riboflavin metabolites
presented by the MHC class I–like molecule MR1. Here, we demonstrate using MR1
tetramers that recipient MAIT cells are present in small but definable numbers in graft-
versus-host disease (GVHD) target organs and protect from acute GVHD in the colon
following bone marrow transplantation (BMT). Consistent with their preferential juxtaposition
to microbial signals in the colon, recipient MAIT cells generate large amounts of IL-17A,
promote gastrointestinal tract integrity, and limit the donor alloantigen presentation that in
turn drives donor Th1 and Th17 expansion specifically in the colon after BMT. Allogeneic
BMT recipients deficient in IL-17A also develop accelerated GVHD, suggesting MAIT cells
likely regulate GVHD, at least in part, by the generation of this cytokine. Indeed, analysis of
stool microbiota and colon tissue from IL-17A–/– and MR1–/– mice identified analogous
shifts in microbiome operational taxonomic units (OTU) and mediators of barrier integrity
that appear to represent pathways controlled by similar, IL-17A–dependent mechanisms.
Thus, MAIT cells act to control barrier function to attenuate pathogenic T cell responses in
the colon and, given their very high frequency in humans, likely represent an important
population in clinical BMT.
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Introduction
Acute graft-versus-host disease (GVHD) remains a major complica-
tion of allogeneic bone marrow transplantation (BMT) and results in 
considerable morbidity and mortality. Major target organs include 
the gastrointestinal (GI) tract, liver, and skin, all of which represent 
tissues with extensive environmental interfaces (1). Acute GVHD is 
initiated during conditioning when inflammation invoked by chemo-
radiotherapy serves to enhance antigen-presenting cell (APC) func-
tion and the costimulation of T cells in tissue (1). Recipient alloan-
tigens are thus presented to donor T cells that differentiate along 
proinflammatory lineages defined by Th1 and Th17 paradigms (2). 
Target organ damage is mediated by both inflammatory cytokines 
generated by T cells and mononuclear cells together with T cell 
cytotoxic pathways. Danger-associated molecular pattern (DAMP) 
and pathogen-associated molecular pattern (PAMP) signaling by- 
products of cellular damage induced by chemoradiotherapy and 
microbiome-derived products are critical in driving this system-wide 
inflammation (2, 3).
The primacy of the GI tract in controlling the severity of GVHD 
is well established (4), and it is increasingly clear that, as the epithe-
lial barrier loses integrity, microbiota-derived PAMPs induce the 
release of IL-17 and IL-22, among other cytokines, whose primary 
function is to limit pathogen spread. IL-17 in the GI tract is pro-
duced by conventional T cells, γδ T cells, and the recently described 
mucosal-associated invariant T (MAIT) cells (5–7), the latter of 
which are exquisitely positioned to respond to microbial invasion 
by nature of their residence within the lamina propria of the small 
and large intestine (6–9). MAIT cells typically express semiinvari-
ant T cell receptor (TCR) repertoires consisting of TRAV1 (Vα19 
in mice or Vα7.2 in humans) joined to Jα33 (also Jα12 and Jα20 in 
humans) and limited TCRβ chain pairing (19 and 13 in mice, 6 and 
20 in humans) (10). These innate-like T cells respond to vitamin 
B2– and B9–derived metabolites presented by the MHC class I–like 
molecule MR1 to rapidly secrete effector cytokines (11–15). The 
riboflavin-based precursors are produced by a range of bacteria, 
Mucosal-associated invariant T (MAIT) cells are a unique innate-like T cell subset that responds to a wide array of bacteria and 
yeast through recognition of riboflavin metabolites presented by the MHC class I–like molecule MR1. Here, we demonstrate 
using MR1 tetramers that recipient MAIT cells are present in small but definable numbers in graft-versus-host disease (GVHD) 
target organs and protect from acute GVHD in the colon following bone marrow transplantation (BMT). Consistent with their 
preferential juxtaposition to microbial signals in the colon, recipient MAIT cells generate large amounts of IL-17A, promote 
gastrointestinal tract integrity, and limit the donor alloantigen presentation that in turn drives donor Th1 and Th17 expansion 
specifically in the colon after BMT. Allogeneic BMT recipients deficient in IL-17A also develop accelerated GVHD, suggesting 
MAIT cells likely regulate GVHD, at least in part, by the generation of this cytokine. Indeed, analysis of stool microbiota and 
colon tissue from IL-17A–/– and MR1–/– mice identified analogous shifts in microbiome operational taxonomic units (OTU) 
and mediators of barrier integrity that appear to represent pathways controlled by similar, IL-17A–dependent mechanisms. 
Thus, MAIT cells act to control barrier function to attenuate pathogenic T cell responses in the colon and, given their very high 
frequency in humans, likely represent an important population in clinical BMT.
Recipient mucosal-associated invariant T cells  
control GVHD within the colon
Antiopi Varelias,1,2 Mark D. Bunting,1 Kate L. Ormerod,3 Motoko Koyama,1 Stuart D. Olver,1 Jasmin Straube,4 Rachel D. Kuns,1 
Renee J. Robb,1 Andrea S. Henden,1,5 Leanne Cooper,4 Nancy Lachner,3 Kate H. Gartlan,1,2 Olivier Lantz,6 Lars Kjer-Nielsen,7  
Jeffrey Y.W. Mak,8 David P. Fairlie,8 Andrew D. Clouston,9 James McCluskey,7 Jamie Rossjohn,10,11,12 Steven W. Lane,2,4,5  
Philip Hugenholtz,3 and Geoffrey R. Hill1,2,5
1Bone Marrow Transplantation Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia. 2Faculty of Medicine, and 3Australian Centre for Ecogenomics, The University of Queensland, 
Brisbane, Australia. 4Gordon and Jessie Gilmour Leukaemia Research Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia. 5The Royal Brisbane and Women’s Hospital, Brisbane, 
Australia. 6INSERM U932 and Department de Biologie des Tumeurs, Institute Curie and Centre d’Investigation Clinique, CICBT507 IGR/Curie, Paris, France. 7Department of Microbiology and Immunology, 
Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Australia. 8Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular 
Bioscience, The University of Queensland, Brisbane, Australia. 9Envoi Specialist Pathologists, Brisbane, Australia. 10Infection and Immunity Program and The Department of Biochemistry and Molecular 
Biology, Biomedicine Discovery Institute Monash University, Clayton, Australia. 11Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom. 12Australian Research 
Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Australia.
Authorship note: AV and MDB contributed equally to this work.
Conflict of interest: LKN, JR, JM, and DPF are named inventors on a patent application 
(PCT/AU2013/000742, WO2014005194). LKN, JYWM, JR, JM, and DPF are named inventors 
on a patent application (PCT/AU2015/050148, WO2015149130) involving MR1 ligands for 
MR1-restricted MAIT cells owned by University of Queensland, Monash University, and 
University of Melbourne.
Submitted: November 7, 2016; Accepted: February 16, 2018.
Reference information: J Clin Invest. https://doi.org/10.1172/JCI91646.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 jci.org
Figure 1. MAIT cells are present in GVHD target organs. Lymphocytes from 
naive mouse peripheral blood (A), liver (B), lung (C), SI (D), and colon (E) 
were stained with the MR1 tetramer (5-OP-RU) or control tetramer (6-FP) 
and analyzed by flow cytometry. Gates were set based on the control 
tetramer and cells from MR1–/– mice. Mouse MAIT cells were defined as 
CD3+. Representative dot plots are shown.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3jci.org
Vα7.2 and CD161, where they are found in relatively high fre-
quencies in the blood, liver, and GI tract (8, 23). However, identi-
fication of mouse MAIT cells using readily available surface mark-
ers is not feasible due to an absence of reagents and a specific 
surface-marker phenotype to distinguish these cells from con-
ventional T cells. Using mouse MR1 tetramers loaded with either 
an activating MAIT cell ligand (5-[2-oxopropylideneamino]- 
6-d-ribitylaminouracil [5-OP-RU]) or a nonactivating ligand 
(6-formylpterin [6-FP]) (7, 11) we were able to screen and specifi-
cally identify mouse MAIT cells by flow cytometry in various organs 
from naive mice. Lymphocytes from the peripheral blood, liver, 
lungs, small intestine (SI), and colon of naive mice were stained 
with the common T cell markers CD3, CD4, and CD8 and the MR1 
tetramers described herein. MR1–/– mice, which lack MAIT cells, 
were used as an additional control to show specificity of the MR1 
tetramer. MAIT cells were mostly CD3+CD4negCD8neg, with much 
smaller numbers of CD3+CD4+ and CD3+CD8+ MAIT cells, and this 
varied among the tissues examined, consistent with recent studies 
(6–8). Compared to peripheral blood (Figure 1A), a higher frequen-
yeast, and fungi (and not mammalian cells), such as Escherichia 
coli, Staphylococcus aureus, Mycobacterium tuberculosis, Salmonel-
la typhimurium, Pseudomonas aeruginosa, Klebsiella pneumoniae, 
Lactobacillus acidophilus, and Candida albicans, to mention a few 
(16). This unique activation pathway provides an additional mech-
anism of determining nonself from self. Previous work in murine 
models and humans has shown that MAIT cells possess potent 
antimicrobial functions, primarily due to the rapid, diverse, and 
expansive cytokine production by these cells (6, 16–22). However, 
a role for MAIT cells in transplantation outcomes has not been 
reported to date. We hypothesized that MAIT cells would be intri-
cately involved in regulating GVHD, as they are located at mucosal 
sites where GVHD manifests. We thus have utilized MAIT cell–
deficient MR1–/– mice and MR1 tetramers (7, 8, 11) to characterize 
the role of MAIT cells in the context of BMT.
Results
MAIT cells are present in GVHD target organs. MAIT cells were tra-
ditionally identified in adult humans using the surface markers 
Figure 2. Recipient MAIT cells provide protection from GVHD. (A and B) G-CSF–mobilized BALB/c.WT splenocytes (25 × 106) were transplanted to lethally 
irradiated B6.WT or B6.MR1–/– mice and survival and clinical scores monitored. Data pooled from 2 independent experiments. n = 12 per group; TCD group,  
n = 3. (C and D) Grafts composed of B6.WT BM (5 × 106) and B6.WT T cells (2 or 5 × 106 as indicated) or B6.MR1–/– BM and B6.MR1–/– T cells were transplanted 
into lethally irradiated B6D2F1 recipients and survival and clinical scores determined. Data combined from 2 independent experiments are shown. n = 16 per 
group; TCD group, n = 7. (E and F) Lethally irradiated B6D2F1 recipients were transplanted with G-CSF–mobilized splenocytes (10 × 106) from B6.WT or B6.MR1–/– 
donors. Data combined from 2 replicate experiments are shown. n = 16 per group; TCD group, n = 6 mice. Survival represented by Kaplan-Meier analysis.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 jci.org
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
5jci.org
ing on the disease model used (24–28). We investigated the func-
tion of MAIT cells in a major MHC-mismatched allogeneic trans-
plant setting. C57BL/6 WT (B6.WT) or MR1-deficient mice on 
a B6 background (B6.MR1–/–) were lethally irradiated and trans-
planted with granulocyte colony stimulating factor–mobilized 
(G-CSF–mobilized) BALB/c spleen grafts (stem cell transplant 
[SCT]). G-CSF–mobilized T cell–depleted (TCD) BALB/c spleno-
cytes were also included as a non-GVHD control, and survival and 
clinical scores were assessed. B6.WT and B6.MR1–/– recipients 
showed a median survival time of 56 days and 19 days, respec-
tively, corresponding to a significant reduction in survival (Figure 
2A). Clinical scores of B6.MR1–/– recipients were also significantly 
higher from day 14 to day 28 after transplant (Figure 2B). GVHD 
lethality was also increased in B6.MR1–/– relative to B6.WT recipi-
ents that received grafts from LP/J donors that were mismatched 
for minor histocompatibility antigens only (day 70 survival, 33% 
versus 100%; P = 0.02). These data indicate that recipient MAIT 
cells function in a regulatory manner in the setting of GVHD. 
To determine whether donor-derived MAIT cells contributed to 
regulation of GVHD, B6D2F1 mice were lethally irradiated and 
transplanted with either B6.WT or B6.MR1–/– BM and T cells in 
a major MHC-mismatched model. Notably, naive B6.MR1–/– ani-
mals exhibited no perturbation of the conventional T cell com-
partment with respect to abundance and subsets (Supplemental 
Figure 1, A and B; supplemental material available online with 
this article; https://doi.org/10.1172/JCI91646DS1), suggesting 
that any effect on survival was due to the absence of MAIT cells 
alone. Survival and clinical scores were similar between B6.WT 
and B6.MR1–/– donor grafts (Figure 2, C and D). We also per-
formed transplants in a second system using G-CSF–mobilized 
donor grafts from B6.WT and B6.MR1–/– mice into B6D2F1 recip-
cy of MAIT cells was noted in the liver (Figure 1B), lung (Figure 1C), 
SI, and colon (Figure 1, D and E), approximating 3%–4% of gated 
CD3+CD4negCD8neg cells, as defined by binding of the active MR1 
tetramer. Fractionation of the SI and colon tissue into intraepithelial 
and lamina propria compartments revealed that MAIT cells resided 
exclusively within the lamina propria (data not shown). Addition-
ally, detection of MR1 tetramer–positive cells in the spleen, lymph 
nodes (LNs), and bone marrow was negligible (data not shown), 
highlighting the mucosal-associated nature of mouse MAIT cells. 
These data support those recently published using MR1 tetramers 
(6, 7) and suggest that MAIT cells may have a role to play in GVHD 
due to their localization in GVHD target organs and juxtaposition to 
potential environmental stimuli.
Recipient MAIT cells abrogate GVHD induced by allogeneic stem 
cell transplantation. Prior study of the function of MAIT cells has 
shown both proinflammatory and regulatory functions, depend-
Figure 3. Recipient MAIT cells attenuate acute GVHD within the GI tract. 
B6.WT and B6.MR1–/– mice were transplanted with G-CSF–mobilized 
BALB/c.WT splenocytes or TCD splenocytes. (A) Serum cytokine analysis 
was conducted on days 4, 7, and 14 after transplant. Day 4 data from 1–2 
experiments. n = 5–10 per group; day 7 data pooled from 2 independent 
experiments, n = 11–12 per group; day 14 data from 1 experiment. n = 6–7 
per group. (B–E) Semiquantitative histopathology of liver (B), lung (C), SI 
(D), and colon (E) from B6.WT and B6.MR1–/– recipients at days 13–14 after 
SCT. Images were captured on a Nikon ECLIPSE Ci microscope fitted with 
a DS-Fi2 camera. Original magnification, ×4. Data combined from 2 inde-
pendent experiments, n = 9–12 per group; TCD group, n = 6. (F) Perturbed 
intestinal barrier integrity as determined by FITC-dextran levels in serum 
on day 13 after SCT. All data analyzed using the Mann-Whitney U test 
except histology data, which was analyzed using the unpaired t test with 
Welch’s correction.
Figure 4. Recipient MAIT cells within the 
GI tract persist after BMT. B6.WT mice 
were lethally irradiated and transplanted  
with 10 × 106 BALB/c BM and 3 × 106 
BALB/c T cells. Recipient lamina propria 
lymphocytes from the SI (A) and colon (B) 
isolated at day 3 and day 7 after trans-
plant were stained with control and MR1 
tetramer and analyzed by flow cytometry. 
Representative dot plots of host CD45+ 
CD3+CD4negCD8neg cells additionally stained 
with γδ TCR and MR1 tetramer are shown. 
Quantification of MAIT cell numbers before 
and after transplant for the SI and colon is 
shown below plots. Enumeration of recip-
ient γδ T cells from the same samples is 
shown for comparison. Numbers on graph 
show average percentage of reduction in 
absolute numbers compared with that in 
naive mice. Data from 1 or 2 experiments.  
n = 3–5 mice per time point.
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ients. This also showed no difference in survival between the 2 
groups (Figure 2, E and F), demonstrating that in these preclinical 
settings, it is recipient MAIT cells that abrogate GVHD.
Regulatory function of MAIT cells is confined to the GI tract. 
We established that recipient-derived MAIT cells appear to play 
a regulatory role during GVHD. To garner further understanding 
of the regulatory nature of MAIT cells in vivo, we analyzed serum 
cytokine levels in B6.WT and B6.MR1-deficient recipient mice 
after allogeneic SCT over a time course, with the aim of identify-
ing when recipient MAIT cell activity might peak. Levels of serum 
IL-1β, IL-4, IL-5, IL-6, TNF, IFN-γ, and GM-CSF were similar 
between B6.WT and B6.MR1–/– recipients at day 4 after SCT (Fig-
ure 3A). A significant increase in IL-6 and TNF was observed at 
day 7 after SCT in B6.MR1–/– mice compared with B6.WT, but was 
not apparent at day 14 (Figure 3A), indicating the regulation pro-
vided by MAIT cells may be occurring in the early phase of GVHD. 
These data also suggested that the effect may be organ specific, 
as the serum cytokine levels in B6.MR1–/– animals were unlikely to 
account for the significant reduction in survival observed.
We thus undertook semiquantitative histopathology of the 
liver, lung, SI, and colon of B6.WT and B6.MR1–/– recipients after 
transplant. These analyses failed to identify any differences in the 
lung, liver, and SI (Figure 3, B–D). In contrast, pathology was sig-
nificantly increased in the colon of B6.MR1–/– recipients (Figure 
3E) and displayed perturbed barrier integrity (Figure 3F), sug-
gesting GI tract–associated MAIT cells abrogated the pathology 
occurring in these tissues, thus improving survival. In order to 
regulate disease during GVHD, recipient MAIT cells must sur-
vive conditioning and the incoming alloreactive donor graft in 
the early transplant period. To establish whether this was indeed 
the case, we performed transplants in B6.WT mice and used the 
MR1 tetramer to identify recipient MAIT cells by flow cytometry. 
Recipient MAIT cells were identified in the SI and colon on day 
3 and day 7 after transplant (Figure 4, A and B). Although their 
abundance was reduced compared with levels seen in naive 
mice, the relative reduction in recipient MAIT cells after BMT 
was equivalent to that of recipient γδ T cells (Figure 4, A and B), 
another innate T cell population. Thus, recipient MAIT cells sur-
vive early after transplant with kinetics similar to those of other 
innate-like T cell populations.
Tregs play a key role in maintaining intestinal homeostasis 
(29), and their induction by particular microbiota (30, 31) and 
microbial-derived metabolites has been described (32, 33). We 
thus examined Tregs in the colon lamina propria in WT and 
MR1–/– mice at day 14 after SCT. This revealed no difference in 
Treg frequency or number between the 2 groups (Supplemental 
Figure 5. Recipient MAIT cells attenuate proinflammatory donor CD4+ T cell expan-
sion in the colon. (A) B6.WT and B6.MR1–/– mice were lethally irradiated, transplanted 
with BALB/c.WT BM (10 × 106) and BALB/c.luciferase+ T cells (3 × 106) and organs 
imaged at days 7 and 14 after transplant. Representative BLI images of the spleen, 
liver, lung, and GI tract (including mLNs) are shown. (B) Quantitated BLI at days 7 
(top) and 14 (bottom) is shown. Data are pooled from 2 independent experiments for 
each time point. Day 7, n = 5–7 per group; day 14, n = 11 per group. (C) Frequency of 
proliferating donor CD4+ T cells in the colon lamina propria at day 14, as determined 
by intracellular Ki-67 expression. (D) Frequency of apoptotic donor CD4+ T cells in 
the colon lamina propria at day 14, as determined by intracellular active caspase-3 
expression. Data combined from 2 replicate experiments are shown. n = 5 – 9 per 
group. Data analyzed using the Mann-Whitney U test.
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Figure 2), demonstrating that MAIT cells do not have a direct 
impact on Tregs and do not appear to regulate the severity of 
GVHD via this regulatory lineage.
To determine the effect recipient-derived MAIT cells have on 
donor T cell expansion after transplant, we conducted transplants 
using luciferase-expressing donor T cells injected together with 
(luciferase negative) BM into either B6.WT or B6.MR1-deficient 
recipients. This enabled us to quantify the level of donor T cell 
expansion in the presence or absence of MAIT cells in various 
organs at any given time point. Whole-body imaging at day 7 and 
day 14 after transplant did not show any difference in the biolu-
minescent imaging (BLI) signal of B6.WT and B6.MR1–/– mice 
(data not shown). We thus conducted organ imaging at the same 
time points to look for organ-specific effects. The BLI signal orig-
inating from spleen, liver, lung, mesenteric LN (mLN), SI, cecum, 
and colon at day 7 was equivalent between B6.WT and B6.MR1–/– 
mice (Figure 5, A and B). In contrast, we observed a significant 
increase in the BLI signal of the cecum and colon in B6.MR1–/– 
mice compared with WT at day 14 after transplant (Figure 5, A 
and B). To determine whether the increased BLI in the colon was 
due to donor T cell migration and expansion and/or survival, we 
assessed donor T cell proliferation (Ki-67 expression) and apop-
tosis (active caspase-3 expression) in the colon lamina propria at 
day 14 after transplant. This revealed an increase in the frequency 
of proliferating CD4+ T cells in MR1-deficient mice compared 
with WT without a clear reduction in apoptosis (Figure 5, C and 
D). Differences in CD8+ T cell proliferation and apoptosis were 
not evident (Supplemental Figure 3, C and D). These data suggest 
that recipient MAIT cells constrain the alloreactive-driven expan-
sion of donor T cells specifically in the colon. In support of this, 
we observed only minor differences in the frequencies or absolute 
numbers of CD4+ and no changes in CD8+ T cells in the spleen 
and mLNs of B6.WT and B6.MR1–/– mice at day 7 or day 13 after 
transplant (Supplemental Figure 3, A and B).
Figure 6. Recipient MAIT cells attenuate proinflammatory donor CD4+ T cell expan-
sion in the colon and secrete IL-17. B6.WT and B6.MR1–/– mice were transplanted as 
in Figure 5A. Colon-derived lamina propria lymphocytes at day 14 after transplant 
were isolated and stimulated in vitro with PMA/ionomycin, followed by assessment 
of IFN-γ and IL-10 production (A) and IL-17A and TNF-α production (B) by donor CD4+ T 
cells using intracellular flow cytometry. Quantification of frequency (top) and absolute 
number (bottom) of cytokine-producing donor CD4+ T cells. Each point represents cells 
from pooled colons of 2 mice. Data from 2 independent experiments. n = 4–6 mice per 
group. (C) CD3+CD4negCD8neg (DN), CD3+CD4+CD8neg, and CD3+CD8+CD4neg cells were sort 
purified from B6.WT and B6.MAIT Tg LNs, stimulated in vitro with α-CD3/α-CD28 for 
72 hours, and cytokines determined in culture supernatant. Data from 2 independent 
experiments with 2–3 WT and 6–8 MR1–/– mice pooled per group. Data analyzed using 
the Mann-Whitney U test.
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Figure 7. MAIT cells in the GI tract are constitu-
tively activated in steady state and preferentially 
express IL-17 in the colon. (A) Representative 
histograms showing CD69 (red overlay; isotype, gray 
histogram) and IL-17eYFP (solid black) expression 
on recipient MAIT cells in the colon, SI, lung, liver, 
and spleen in steady-state and after allogeneic SCT 
(d+1). (B and C) Number of CD69+ and IL-17eYFP+ 
MAIT cells in tissues was quantified. Data pooled 
from 4 replicate experiments are shown. Colon, 3 
experiments (n = 6–12); SI, 3 experiments (n = 6–10); 
liver, 2 experiments (n = 4–8); lung, 2 experiments  
(n = 4–8); spleen, 2 experiments (n = 3–4).
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B6.MR1–/– recipients (Figure 6, A and B), but not SI (Supplemental 
Figure 5, A–D). This included increased frequencies and numbers 
of IFN-γ+–, IL-17+IFN-γ+–, and TNF-α+–producing colonic donor 
CD4+ T cells. Concomitantly there was a small decrease in IL-10– 
producing donor CD4+ T cells in the colon of MR1–/– mice (Figure 
6A). This phenomenon was predominantly restricted to the CD4 
lineage, as cytokine production by colonic CD8+ donor T cells was 
similar between B6.WT and B6.MR1–/– mice (Supplemental Figure 
To extend these findings, with the aim of establishing which 
proinflammatory population or populations may be suppressed by 
MAIT cells, we analyzed the cytokine production of donor T cells 
by intracellular cytokine staining. Small but significant increases in 
polyfunctional (IFN-γ+IL-17+) donor CD4+ T cells were seen in mLNs 
of B6.MR1–/– mice 7 days after transplant (Supplemental Figure 4, A 
and B). Subsequently, increased numbers of polyfunctional donor 
CD4+ T cells were observed in the lamina propria of colons from 
Figure 8. MAIT cells appear to shape the GI microbiome. (A) PCA plot of 16S rRNA-seq data generated from fecal samples collected from B6.WT and 
B6.MR1–/– mice either before and after cohousing or when separately housed. Each dot represents an individual mouse, with symbols and colors corre-
sponding to the genetic background and time point. Data combined from 3 independent experiments. Experiment 1, n = 6 mice per group; experiments 2 
and 3, n = 5 mice per group. (B) Heatmap showing significantly different OTUs between before and after cohousing samples in either B6.WT or B6.MR1–/– 
mice. OTUs displaying consistent movement in all 3 experiments are shown. Details contained in Supplemental Tables 1 and 2. (C) Separately housed or 
cohoused B6.WT and B6.MR1–/– mice were transplanted and clinical scores and survival monitored. Data pooled from 3 independent experiments. n = 15 
mice per group; TCD group, n = 9. Survival data analyzed with a log-rank test. ****P < 0.0001; **P = 0.0016 (cohoused B6.WT versus cohoused B6.MR1–/–); 
**P = 0.0012 (cohoused B6.WT versus separate B6.MR1–/–). (D) PCA plot combining data from A with sequencing data from fecal samples collected after 
transplant. Data combined from 2 independent experiments. Experiments 2 and 3, n = 5–10 mice per group. 16S rRNA-seq data analyzed using DESeq2.
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early after SCT (day +1) using IL-17eYFP fate reporter mice. Strik-
ingly, MAIT cells in the GI tract displayed an activated phenotype 
with constitutive expression of CD69 at steady state (Figure 7, A and 
B). Analysis of IL-17 fate reporter expression (eYFP) further demon-
strated that recipient MAIT cells in the colon expressed high levels 
of IL-17, even at steady state (Figure 7, A and C). This high number of 
activated MAIT cells expressing IL-17 in the colon is consistent with 
the preferential effects of this lineage specifically in the colon. Thus, 
MAIT cells in the colon, unlike those in any other organ examined, 
are both activated and high IL-17 producers at all times, represent-
ing a population poised to respond rapidly to bacterial metabolite 
antigens and regulate acute GVHD.
MAIT cells appear to regulate microbiome diversity in the GI tract. 
Previous studies have demonstrated that the microbiota and their 
microbial metabolites can profoundly influence intestinal inflam-
mation during GVHD (35, 36), and in a nontransplant setting, IL-17 
has been shown to regulate this interplay (37). The data thus far 
6, A and B). These data demonstrate that colon-associated MAIT 
cells suppress the expansion of polyfunctional, proinflammatory 
donor Th1 and Th17 cells in the colon during GVHD.
We next analyzed the cytokine profile of sorted CD3+CD4neg-
CD8neg, CD3+CD4+, and CD3+CD8+ T cells from WT and MAIT 
Tg mice, which contain only Vα19+Vβ6+ MR1 tetramer–reactive T 
cells. MAIT cells produced significantly higher levels of IL-17A, 
IL-17F, IFN-γ, and TNF-α, with the majority of cytokine production 
attributed to CD3+CD4negCD8neg MAIT cells (Figure 6C). These 
findings are consistent with recent reports using a similar MAIT 
Tg mouse (9, 14, 19, 25, 34) or polyclonal murine (7, 21) or human 
MAIT cells (20) and highlight the significant IL-17 response gen-
erated by these cells.
Given that our data showed that the regulatory function of MAIT 
cells was restricted to the colon (Figure 3), we investigated why this 
may be the case by examining the activation status and IL-17 expres-
sion of MAIT cells from various target tissues in naive animals and 
Figure 9. Analogous alterations in the microbiome in the absence of MAIT cells and IL-17A. (A) Separately housed B6.WT and B6.IL-17A–/– mice were 
transplanted with 25 × 106 G-CSF–mobilized BALB/c splenocytes, and clinical scores and survival were monitored. Data pooled from 2 independent experi-
ments (n = 10 per group; TCD group, n = 3; B6.IL-17A–/– TCD group, n = 5). Survival data analyzed with a log-rank test. P < 0.0001, B6.WT versus B6.IL-17A–/–. 
(B) Fecal samples collected from naive B6.WT and B6.IL-17A–/– mice were profiled by 16S rRNA-seq. Principal component analysis of B6.WT, B6.IL-17A–/–, and 
B6.MR1–/– (Figure 7A data set) data demonstrates distinct OTU profiles. Each dot represents an individual mouse, with symbols and colors corresponding 
to the genetic background and experiment. Data from 4 experiments are shown. Experiment 1, WT versus MR1–/–, n = 6 mice per group; experiments 2 and 
3, WT versus MR1–/–, n = 4-5 mice per group; experiment 4, WT versus IL-17A–/–, n = 8-10 mice per group. (C) Heatmap showing significantly different OTUs 
between naive B6.IL-17A–/– and B6.MR1–/– mice in comparison with B6.WT mice from the same samples as used in B. Details contained in Supplemental 
Table 3. 16S rRNA sequencing data analyzed using DESeq2.
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units (OTU) displaying analogous abundance shifts in both dele-
tion strains in comparison with B6.WT mice, thereby potentially 
representing populations controlled by similar, IL-17A–dependent 
mechanisms (Figure 9C and Supplemental Table 3). These data 
indicate that, in the absence of host-derived MAIT cells, a dysbi-
otic microbial community is established, some of which is IL-17A 
dependent, but this does not contribute directly to GVHD. The 
increased mortality of B6.MR1–/– mice may instead be associated 
with the loss of an important recipient IL-17–producing cell, since 
this cytokine is clearly protective during the early phase of GVHD.
MAIT cells regulate barrier integrity and restrain alloantigen 
presentation and effector T cell expansion. As increased mortality 
was observed in both MR1-deficient and IL-17A–deficient mice 
after SCT and we showed that MAIT-derived IL-17A expression 
differed between regions of the GI tract during steady state, we 
sought to determine the possible mechanisms of MAIT/IL-17–
mediated regulatory effects unique to the colon. We undertook 
RNA-sequencing (RNA-seq) analysis of colon and ileum tissue 
from naive WT, MR1–/–, and IL-17A–/– mice. Analysis of the differ-
entially expressed genes in the colon revealed upregulation of 142 
genes in MR1–/– versus WT, with 67 common genes overlapping 
with upregulated genes seen in IL-17A–/– versus WT (Figure 10A) 
and 216 downregulated genes in MR1–/– versus WT, with 103 com-
mon genes overlapping with downregulated genes observed in 
IL-17A–/– versus WT (Figure 10A). We next filtered out the differ-
entially expressed genes common with ileum and examined the 
top 50 differentially expressed genes unique to colon. The heat-
map shows clusters of differentially expressed genes common 
to both MR1–/– and IL-17A–/– tissues compared with WT (Figure 
10B), with selected genes of known function shown in Table 1. 
Strikingly, claudin 4 (Cldn4) and claudin 8 (Cldn8) gene expres-
sion was downregulated in both MR1–/– and IL-17A–/– mice com-
pared with WT (Figure 10, B and C, and Table 1), suggesting MAIT 
cells may maintain barrier integrity in the colon by modulating 
tight-junction proteins via IL-17A, consistent with data shown 
in Figure 3F. Interestingly, gene expression of Semaphorin 6d 
and 4b (Sema6d and 4b), important regulators of T cell immune 
responses (40, 41), was downregulated in MR1–/– and IL-17A–/– 
mice compared with WT (Figure 10B and Table 1), as was the 
expression of nuclear factor, interleukin 3 regulated (Nfil3) (Fig-
have established that recipient MAIT cells reside in mucosal tis-
sue and regulate GVHD in the colon. Given that the colon is a rich 
source of microbes and MAIT cells respond to microbial metab-
olites, we hypothesized that this cell population may respond to, 
and have an impact on, the gut microbiome. We thus cohoused 
B6.WT with B6.MR1–/– mice to equilibrate the intestinal microbi-
ota prior to transplantation and confirmed that (a) MAIT cells do 
indeed influence the composition of the microbiota and that (b) 
this composition converges with WT after cohousing for a month 
(Figure 8, A and B, and Supplemental Tables 1 and 2). In contrast, 
separately housed mice of each strain analyzed in parallel retained 
their initial GI tract microbiota, confirming the community shift 
was a consequence of cohousing. We next transplanted cohoused 
mice and separately housed mice to establish whether the altered 
microbiota of the cohoused mice affected GVHD. B6.WT mice 
cohoused with B6.MR1–/– mice showed survival kinetics equiva-
lent to those of separately housed B6.WT mice (Figure 8C) and 
displayed a fecal microbial community similar to that of B6.MR1–/– 
mice after transplant (Figure 8D), suggesting that any dysbiotic 
microbial populations present in B6.MR1–/– mice do not directly 
influence GVHD outcome.
Given that recipient MAIT cells produce very high levels 
of IL-17A and that IL-17A is known to be capable of regulating 
inflammatory colitis (38), we analyzed the importance of recipi-
ent-derived IL-17 in GVHD. Indeed, B6.IL-17A–/– mice exhibited 
hyperacute GVHD, with a mean survival time of 7.5 days versus 34 
days for B6.WT mice (Figure 9A). We confirmed that MAIT cells 
were indeed present in tissues from naive IL-17A–/– mice (lung, SI, 
and colon) and in fact were in greater abundance in the colon com-
pared with WT (Supplemental Figure 7, A and B), likely a response 
to the known dysbiosis in these animals (39).Furthermore, we 
showed that upon ex vivo expansion (Supplemental Figure 8) and 
activation, MAIT cells from both WT and IL-17A–/– mice expressed 
IFN-γ and TNF, but not IL-10. As expected, only WT MAIT cells 
expressed IL-17A, demonstrating that MAIT cells from IL-17A–/– 
mice were functionally active (Supplemental Figure 7, C and D). 
Comparison of the microbiota of B6.IL-17A–/– and B6.MR1–/– mice 
revealed that IL-17A depletion was associated with an addition-
al disparate microbial composition (Figure 9B). Despite this, we 
were able to identify a small number of operational taxonomic 
Table 1. Selected genes downregulated in both MR1–/– and IL-17A–/– mice compared with WT
WT versus MR1–/– WT versus IL-17A–/–
Gene Symbol (log) Fold change P value (log) Fold change P value Function
Downregulated
Claudin 4 Cldn4 1.01 2.01 × 10–06 0.666 0.007 Barrier integrity
Claudin 8 Cldn8 0.816 0.019 1.829 3.41171 × 10–13 Barrier integrity
Semaphorin 6d Sema6d 0.432 0.011 0.438 0.005 Regulator of T cell immune responses
Semaphorin 4b Sema4b 0.568 5.48485 × 10–06 0.49 0.0002 Regulator of T cell immune responses
Cathepsin L Ctsl 0.305 0.046 0.363 0.004 Protease; Th17 differentiation
Nuclear factor, interleukin 3 
regulated
Nfil3 1.599 0.0002 2.875 3.09406 × 10–14 Bacterial immune defense
UDP glucuronosyltransferase 
1 family, polypeptide A8
Ugt1a8 4.705 0.008 13.08 1.3403 × 10 × 10–176 Metabolism (glucuronidation pathway)
Data analyzed using edgeR with FDR < 0.05. 
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ing inflammatory diseases that target mucosal surfaces (16, 44). 
Previous work has demonstrated both inflammatory and regula-
tory functions for MAIT cells in various mouse models and human 
disease (8, 9); however, the function of MAIT cells in the context 
of GVHD has not been studied. Using MAIT-deficient mice and 
MR1 tetramers to specifically identify endogenous MAIT cells 
in nongenetically modified mice, we have shown that recipient- 
derived MAIT cells persist in the colon following total body irra-
diation. Here, lamina propria MAIT cells appear to control GVHD 
by regulating barrier function and attenuate proinflammatory 
cytokine production by donor CD4+ T cells. This is associated 
with shifts in the intestinal microbiota.
MAIT cell activation requires presentation of riboflavin-based 
precursors captured by the MHC class I–related molecule MR1 
(11–15). The breakdown of epithelial barrier integrity after BMT, a 
result of chemoradiotherapy during conditioning and GVHD itself 
(4), is likely to increase access of T cells and APCs to bacteria (2) 
that utilize the riboflavin biosynthesis pathway. Subsequent cap-
ture, processing, and presentation of metabolite antigen on MR1 
to recipient MAIT cells will lead to cellular activation and effec-
tor function. In addition, MAIT cells can also be activated in an 
antigen-independent manner by IL-12 and IL-18 (45–47). The end 
result of MAIT cell activation is to limit microbial colonization and 
disease by potential pathogens. In the context of GVHD, it appears 
that while multiple immune pathways are in effect, MAIT cells 
play a notable and nonredundant role. The present study demon-
strates a link between MAIT cells and the composition of the 
gut microbiome in the mouse at steady state. In particular, shifts 
in the abundance of several OTUs from the bacterial family 
S24-7, recently defined as “Candidatus Homeothermaceae” (48), 
are notable in mice lacking MAIT cells. However, while the micro-
biome profile of B6.MR1–/– mice can be transferred to B6.WT 
mice through cohousing, these communities do not appear to 
influence GVHD. This suggests that the transferrable microbiota, 
putatively regulated by MAIT cells, likely those with an active 
riboflavin biosynthesis pathway, are not directly pathogenic in the 
context of GVHD if MAIT cells are present.
The mucosal location of MAIT cells enables rapid sensing of 
any breakdown in mucosal surface integrity and subsequent bac-
terial and/or PAMP molecule translocation, a prominent feature 
of GVHD. The mechanism by which MAIT cells are able to sup-
press inflammation may be directly through cytokines, as we and 
others have demonstrated their ability to generate large amounts 
of cytokines, particularly IL-17A (6, 7, 14). The majority of adult 
MAIT cells exhibit a mature and differentiated phenotype (7), sug-
gesting they are primed for rapid cytokine production following 
stimulation. Notable expression of IL-17 is related to the expres-
sion of high levels of RORγt and low levels of T-bet (6, 7). MAIT 
cell–derived cytokines, particularly IL-17, induce recruitment of 
myeloid cells, such as monocytes/macrophages and neutrophils 
that mediate pathogen clearance, as demonstrated in other dis-
ease models (49–51).
The GI tract contains numerous sources of IL-17 of both 
hematopoietic and nonhematopoietic origin. Nonhematopoietic 
sources of IL-17 in the GI tract include Paneth cells, which have 
been shown to play a role in inflammation (52), while T cell sources 
include αβ, γδ, NKT, innate lymphoid, and MAIT cells (5). IL-17 
ure 10B and Table 1), a transcription factor important in host 
immune defence against pathogens (42), and UDP glucurono-
syltransferase 1 family, polypeptide A8 (Ugt1a8) (Figure 10B  
and Table 1), an enzyme important in the glucuronidation path-
way of metabolism (43).
The accelerated mortality in MR1–/– recipients in the third week 
after transplant with preferential GVHD in the colon suggested an 
enhancement in indirect antigen presentation by donor colon-de-
rived DCs within the mLN, as we recently described (3). We thus 
undertook experiments to investigate the ability of recipient MAIT 
cells to regulate donor DC expansion and alloantigen presentation 
in the GI tract. In order to achieve this, we used TCR Tg Marilyn 
mice in which CD4+ T cells recognize the male H-Y antigen in an 
I-Ab–restricted fashion. We transplanted grafts comprising BM 
from B6.CD11c-GCDL mice (where the luciferase signal is used to 
track donor CD11c+ DC) and B6.Marilyn TCR Tg T cells (to induce 
GVHD) into lethally irradiated male B6.WT and B6.MR1–/– recip-
ients (Figure 11A). Analysis of bacterial distribution by fluores-
cence in situ hybridization 14 days after SCT revealed increased 
bacterial translocation in the GI tract of MRI–/– recipients (Figure 
11B), an effect also seen in IL-17R–/– recipients (39). Consistent 
with increased DAMP signaling in these animals, a significant 
expansion of donor DC (bioluminescence intensity) in the mLN 
in MR1-deficient mice was also observed (Figure 11C), confirm-
ing that recipient MAIT cells can indeed regulate GI tract integrity 
and donor DC expansion and/or migration in the GI tract.
To ascertain whether this donor DC expansion in MR1- 
deficient mice would lead to an increase in T cell priming and 
effector T cell expansion, we transplanted B6.WT BM with 
B6.Marilyn TCR Tg T cells into lethally irradiated male B6.WT 
and B6.MR1–/– recipients. On day 12 after SCT, we transferred 
Marilyn Tg luc+ T cells (here the luciferase signal reports for donor 
alloantigen presentation and subsequent antigen-specific T cell 
expansion; Figure 11D). Alloantigen-specific (Marilyn Tg luc+) T 
cells were preferentially expanded in the GI tract of MR1-deficient 
mice (Figure 11, E and F), with an increased frequency of patho-
genic IFN-γ+IL-17+–secreting effector T cells (Figure 11, G and H). 
Collectively, these data demonstrate that recipient MAIT cells 
have the ability to suppress alloantigen presentation by donor DC 
and subsequent effector T cell expansion following transplanta-
tion, culminating in the attenuation of GVHD.
Discussion
The importance of mucosal immunity and responses to microbi-
ota at environmental interfaces in disease is only now beginning 
to be appreciated. MAIT cells, whose primary role at steady state 
appears to be antimicrobial, are likely to be important in modulat-
Figure 10. Regulation of host defense and metabolism genes by MAIT and 
IL-17A. RNA-seq analysis was performed on tissue from proximal colon and 
distal ileum of naive WT, MR1–/–, and IL-17A–/– mice (n = 4 per group). (A) 
Comparison of the number of overlapping genes differentially expressed 
within the colon; upregulated (upper) and downregulated (lower) genes. (B) 
Heatmap depicting differentially expressed genes comparing MR1–/– and 
IL-17A–/– versus WT colon, but not ileum. log2 transformed, normalized read 
counts were used. (C) Normalized read count data for claudin 4 and claudin 
8 expression are shown. Data analyzed using edgeR with a false discovery 
rate (FDR) < 0.05.
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very large subset of CD8+ T cells in humans, it will be important 
to ascertain whether numerical and/or functional defects in this 
population correlate with alterations in the intestinal microbiome 
and GVHD outcomes in patients.
Methods
Mice. Female C57BL/6J (B6.WT, H-2b), B6D2F1 (H-2b/d), and BALB/c 
(H-2d) mice were purchased from the Animal Resources Centre (Perth, 
Australia). MR1–/– mice on a C57BL/6 background (67) and iVα19/Vβ6 
double-Tg mice on a Cα–/– C57BL/6 background (68) (B6.MAIT Tg) 
were provided by O. Lantz. B6.Marilyn TCR Tg mice (on a Rag2–/– back-
ground) (69) were provided by P. Matzinger (NIH, Bethesda, Maryland, 
USA). To generate Marilyn TCR Tg luciferase+ mice, B6.Marilyn TCR 
Tg mice were crossed with the B6.β-actin–luciferase (CD90.1+) line 
(70) (provided by R Negrin, Stanford University, Stanford, California, 
USA) to generate Marilyn TCR Tg and luciferase+ CD90.1 homozygous 
mice on a B6.Rag2–/– background. B6.CD11c-GCDL mice (71) (provided 
by G. Hammerling, German Cancer Research Centre, Heidelberg, Ger-
many), B6.IL-17Cre × B6.ROSA26eYFP mice (IL-17eYFP) (72) (provided 
by B. Stockinger, Francis Crick Institute, London, United Kingdom; and 
F. Costantini, Columbia University, New York, New York, USA), BALB/c 
luciferase+ mice (73) (provided by R. Negrin), LP/J mice (Jackson Lab-
oratories, catalog 000676), and BALB/c CD45.1+ mice (sourced from 
the Peter MacCallum Cancer Centre, Melbourne, Australia) were bred 
in house. We used age-matched mice in all experiments. Mice were 
housed in microisolator cages and received acidified autoclaved water 
(pH 2.5) after BMT.
Stem cell and BMT. Total body irradiation (1000 cGy, B6 background; 
1100 cGy, B6D2F1) was administered on day –1 (137Cs source at 82 cGy/
min), split into 2 doses separated by 3 hours. Lethally irradiated mice were 
injected intravenously on day 0 with either 10 or 25 × 106 whole or TCD 
splenocytes from donor mice pretreated for 6 days with G-CSF (10 μg/d). 
T cell depletion was performed by incubating splenocytes with hybrid-
oma supernatants containing anti-CD4 (RL172), anti-CD8 (TIB211), 
and Thy1.2 (HO-13-4), followed by incubation with rabbit complement 
(Cedarlane). Alternatively, lethally irradiated mice were injected intra-
venously on day 0 with 5 to 10 × 106 BM cells and 2 to 5 × 106 enriched 
splenic T cells (80%–90% CD3+). TCD grafts containing only 10 × 106 
TCD BM were transplanted as non-GVHD controls.
Assessment of GVHD. The degree of systemic GVHD was assessed 
using a cumulative scoring system that measures changes in 5 clini-
cal parameters: weight loss, posture (hunching), activity, fur texture, 
and skin integrity (maximum index, 10). Mice were monitored daily, 
and those with GVHD clinical scores of 6 or more (74) were sacrificed 
and the date of death deemed as the next day in accordance with insti-
tutional animal ethics guidelines. Organ pathology was determined 
by blinded assessment of formalin-fixed, paraffin-embedded, H&E-
stained sections as described previously (39).
Flow cytometry. CD4 (clone RM4-5), Vβ6 (clone RR4-7), Ki-67 
(clone B.56), active caspase-3 (clone C92-605), and CD25 (clone 
7D4) were all purchased from BD Biosciences. CD90.1 (Thy1.1, 
clone HIS51) was purchased from eBiosciences. CD3 (clone 145-
2C11), CD8 (clone 53-6.7), CD45.1 (clone A20), CD45.2 (clone 104), 
TCRγδ (clone GL3), CD326 (clone G8.8), CD19 (clone 6D5), CD90.2 
(Thy1.2, clone 53-2.1), CD69 (clone H1.2F3), H2Dd (clone 34-2-12), 
FOXP3 (clone 150D), IL-10 (clone JES5-16E3), IL-17A (clone TC11-
8H10.1), IFN-γ (clone XM1.2), and TNF (clone MP6-XT22) were all 
has direct effects on maintaining epithelial barrier integrity. In 
conjunction with IL-22, IL-17A and IL-17F enhance production of 
antimicrobial peptides (53). Furthermore, following colitis damage 
induced by dextran sulfate sodium (DSS), epithelial cells exposed 
to IL-17 and the growth factor FGF2 undergo proliferation to restore 
barrier function and prevent inflammatory bacterial accumulation 
(54). IL-17 derived from γδ T cells has also been shown to increase 
expression of occludin, a tight junction protein critical for main-
taining homeostasis of epithelial cell permeability (55). As such, 
lack of IL-17 leads to increased susceptibility to infection by both 
bacteria and fungi (56–60). Therefore, IL-17 is required to maintain 
epithelial cell barrier function, and perturbation of IL-17 in this con-
text can lead to enhanced inflammation and GI damage. It is thus 
likely that the protection from GVHD in the GI tract by MAIT cells 
reflects their role in maintaining mucosal integrity and that the 
enhanced donor T cell responses seen in the colon in their absence 
reflect enhanced PAMP signaling locally within the GI tract. This 
pathway has recently been shown to be critical in determining the 
severity of GVHD after BMT (2, 3). Given that MAIT cells are but 
one source of IL-17A in the GI tract, it is thus not surprising that their 
absence results in a phenotype intermediate between IL-17A–/– and 
WT recipients. Thus, the exacerbation of GVHD in the absence of 
IL-17A clearly involves multiple additional pathways over and above 
those mediated by MAIT cells. The pathways of regulation utilized 
by MAIT cells and IL-17A can only be definitively dissected by the 
use of cre-based systems that are not yet available, but will enable 
the specific removal of cytokines from MAIT cells. That said, given 
the known ability of IL-17A from conventional donor T cells to 
promote acute GVHD, including within the GI tract (39, 61, 62), 
we do not envisage that the administration of this cytokine to 
patients would be safe.
It is important to note that MAIT cells are a rare (<1%) popu-
lation in relatively clean inbred mice (7) in contrast with humans, 
where they represent up to 5% of peripheral blood T cells and 45% 
of hepatic T cells (20). Thus, the clear propensity to acute GVHD 
in the GI tract in mice lacking MAIT cells is likely to underestimate 
their importance in patients undergoing BMT. In fact, recipient 
MAIT cells have recently been shown to be resistant to myeloab-
lative chemotherapy prior to autologous SCT. Importantly, pre-
transplant MAIT cell numbers were predictive for reductions in 
subsequent infection and inflammatory responses (63), consistent 
with the findings here after allogeneic SCT. The importance of 
GI tract integrity and microbiome-derived metabolites in modu-
lating GVHD have been demonstrated as a very early event after 
BMT (36, 64). Since the numbers of donor MAIT cells in the bone 
marrow and splenic T cell–derived grafts in these experiments 
are very limited, MAIT cell reconstitution primarily reflects bone 
marrow–derived MAIT cells, which are selected in the thymus of 
MR1-bearing double-negative thymocytes (65). This reconstitu-
tion is thus slow (beyond 3 to 4 weeks) and develops after GVHD 
in the GI tract has already occurred. For these reasons, the effect 
of donor MAIT cells is minimal in these preclinical systems, but 
we acknowledge this may not necessarily be true in clinical trans-
plantation, where the number of MAIT cells in blood is much high-
er. Indeed, a recent study has now demonstrated an association 
between donor MAIT cell numbers and gut microbiota after trans-
plantation (66). Now that reagents are available to study what is a 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 5jci.org
Dead Cell Staining Kit (Invitrogen) was utilized to gate viable cells. 
Cells were acquired on a BD LSRFortessa and analyzed with FlowJo 
V9 (Treestar). MR1 tetramers were prepared and used as previously 
described (7, 8, 11, 75).
purchased from BioLegend. Fixation and permeabilization were 
undertaken for intracellular staining (BD Fix/Perm Kit; BD Biosci-
ences) and nuclear staining (Fix/Perm Kit; eBiosciences) according 
to the manufacturer’s instructions. The LIVE/DEAD Fixable Aqua 
Figure 11. Recipient MAIT cells suppress alloantigen-specific Marilyn TCR Tg effector T cell expansion. (A–C) Lethally irradiated male B6.WT and B6.MR1–/– 
recipients were transplanted with TCD B6.CD11c-GCDL BM and B6.Marilyn TCR Tg T cells. Bacterial translocation in ileum tissue by FISH at day 14 after 
allogeneic SCT is shown in B. Individual organs were imaged on day 14 after allogeneic SCT, and BLI data combined from 3 replicate experiments are shown 
in C (n = 12–15 per group). (D–H) Lethally irradiated male B6.WT and B6.MR1–/– recipients were transplanted with B6.WT BM and B6.Marilyn TCR Tg T cells, 
followed by transfer of Marilyn luc+ T cell on day 12 after allogeneic SCT. Individual organs were imaged 7 days after transfer, and BLI data combined from 3 
replicate experiments are shown in E (n = 9–13 per group). Representative images are shown in F. Frequency of pathogenic IFN-γ+IL-17+ Marilyn luc+ T cells in 
mLN was determined, and data combined from 2 replicate experiments are shown in G (n = 5–10 per group). Representative FACS plots are shown in H. Data 
analyzed using the Mann-Whitney U test. 
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Plus Mini Kits per the manufacturer’s instructions. RNA libraries 
were prepared using the NEBnext Ultra RNA Library Prep Kit for Illu-
mina (New England Biolabs), assessed for size, and quantified using 
the 2100 Bioanalyzer (Agilent Technologies) and Qubit Fluorometer 
(Thermo Fisher Scientific), respectively. Libraries were sequenced 
using high-output single-end 75 cycle sequencing kits (version 2) on 
the Illumina NextSeq 550 platform. Full details are provided in Sup-
plemental Methods. Sequencing data have been uploaded into Array-
Express, accession number E-MTAB-6547.
Statistics. Survival curves were plotted using Kaplan-Meier esti-
mates and compared by log-rank analysis. The parametric unpaired t 
test or the nonparametric Mann-Whitney U or t tests (2-sided) were 
used for the statistical analysis of data. P < 0.05 was considered statis-
tically significant. Data are presented as mean ± SEM.
Study approval. All animal procedures were carried out with 
approval from the QIMR Berghofer Medical Research Institute Ani-
mal Ethics Committee.
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Cytokine bead array. Serum and culture supernatant cytokine 
levels were measured using mouse Flex Array sets (BD Biosciences) 
according to the manufacturer’s instructions.
Barrier integrity assay. Gut permeability was determined by 
FITC-dextran assay, as described previously (39). Bacterial translo-
cation in tissues by FISH was performed as described previously (39).
Xenogen imaging. Donor T cell and DC expansion in vivo was mea-
sured by luciferase signal intensity using the IVIS Spectrum Imaging 
System (Caliper Life Sciences). Mice were injected with luciferin (0.5 
mg) subcutaneously and imaged after 5 minutes. Individual organs 
were harvested and imaged after reinjection with luciferin. Data were 
analyzed using Living Image software (PerkinElmer). Light emis-
sion is presented as photons per second per cm2 per steer radiant 
(ph/cm2/s/sr).
Lymphocyte isolation from tissues. Lymphocytes were isolated from 
colon and SI using the gentleMACS Dissociator and Mouse Lamina 
Propria Dissociation Kit (both Miltenyi Biotech) according to the man-
ufacturer’s instructions. Lymphocytes were isolated from lung tissue 
by digestion with collagenase III as described previously (76) and from 
liver tissue by mechanical disruption and Percoll density centrifuga-
tion as described previously (77).
MAIT cell expansion ex vivo. This was performed as described 
previously (7). Briefly, spleens and thymus from naive B6.WT and 
IL-17A–/–– mice were harvested, mashed, and erythrocytes lysed using 
Gey’s solution. Cells were resuspended in IMDM supplemented with 
152 nM MR1 ligand (5-OP-RU synthesized in DMSO; ref. 78), 50 ng/
ml recombinant human IL-2 (Proleukin; Prometheus Laboratories, 
Bayer HealthCare Pharmaceuticals), 10% FBS, l-glutamine (2 mM), 
penicillin (100 units/ml), streptomycin (100 μg/ml), sodium pyruvate 
(1 mM), NEAA (1×), and 2-β-mercaptoethanol (23 μM). After 5 days 
culture, cells were collected and stimulated with phorbol myristate 
acetate (50 ng/ml) and ionomycin (500 ng/ml) in fresh culture medium 
for 18 hours (brefeldin A added in the final 4 hours). Activated cells 
were then collected and stained for intracellular IFN-γ, TNF, IL-17A, 
and IL-10 expression as described previously (39).
16S rRNA amplicon sequencing and analysis. DNA was extracted 
from 50–100 mg of fecal material using the Maxwell 16 Tissue DNA 
Kit (Promega). The 16S rRNA gene encompassing the V6 to V8 regions 
was amplified and sequenced on the MiSeq Sequencing System (Illu-
mina) using paired-end sequencing with V3 300 bp chemistry in the 
Australian Centre for Ecogenomics according to the manufacturer’s 
protocol. OTUs were identified using the QIIME script pick_open_ 
reference_otus.py (79) with default parameters (97% similarity) and 
assigned taxonomy using BLAST (80) against the Greengenes ref-
erence database version 2014/0955 (http://data.ace.uq.edu.au/ 
public/gg). Differential abundance analysis was performed on raw 
read counts using DESeq2. Full details are provided in the Supplemen-
tal Methods. Sequencing data have been uploaded to the Sequence 
Read Archive under BioProject PRJNA433452.
RNA-seq and analysis. Total RNA was isolated from proximal colon 
and distal ileum tissue using Precellys Lysing and QIAGEN RNeasy 
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